Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSe Trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreVemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSe Trial
Type de publicationJournal Article
Year of Publication2017
AuteursMazieres J, Cropet C, Barlesi F, Souquet PJean, Avrillon V, Coudert B, Le Treut J, Piocelle FOrsini, Quere G, Fabre E, Tredaniel J, Wislez M, Huillard O, Dansin E, Moro-Sibilot D, Blons H, Ferretti G, Lonchamp E, Labouret NHoog, Pezzella V, Oukhatar CMahier Ait, Blay J-Y
JournalJOURNAL OF THORACIC ONCOLOGY
Volume12
PaginationS1182-S1183
Date PublishedJAN
Type of ArticleMeeting Abstract
ISSN1556-0864
Mots-clésAcSe, BRAF mutation, NSCLC, vemurafenib